Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

In this closing segment, the speakers summarize the main lessons from the ADC presentations at ESMO 2025 and reflect on how these findings may shape clinical practice. Dr Mouabbi highlights that ADCs have become central to modern breast cancer treatment and notes that their use now spans multiple disease subtypes and treatment stages. He stresses that clinicians must become familiar with the mechanism of action, toxicity patterns, and monitoring requirements for these agents because ADCs will continue to play an important role in future treatment strategies.

The experts emphasize the need for proactive supportive care. They discuss the importance of early use of growth factors for sacituzumab govitecan, mouthwash protocols for mucositis management with datopotamab deruxtecan, and careful monitoring for interstitial lung disease with trastuzumab deruxtecan. These measures help maintain treatment intensity and reduce the risk of discontinuation due to toxicity.

Dr Tarantino reflects on the significance of the year’s data, noting that ADCs are now moving into curative intent settings. He emphasizes that preventing recurrence with ADCs represents an important development and may help reduce long term disease burden for patients with HER2 positive disease. He also notes that expanded treatment options for HER2 low and triple negative disease mark a meaningful shift in available therapy.

The section concludes with final commentary on the rapid evolution of the ADC field. The speakers encourage clinicians to follow ongoing and upcoming trial readouts because ADCs continue to advance at a fast pace. They express optimism for continued progress and thank the audience for engaging in the discussion.